SPL028

Pharmaceutical compound From Wikipedia, the free encyclopedia

SPL028, or SPL-028, also known as α,α-dideutero-N,N-dimethyltryptamine (D2-DMT), is a psychedelic drug of the tryptamine family which is under development for the treatment of depressive disorders.[2][3][4][5] It is the analogue of dimethyltryptamine (DMT) in which the α carbon has been dideuterated.[2][6] SPL028's route of administration is intravenous injection or intramuscular injection.[1]

Other namesSPL-028; α,α-Dideutero-N,N-dimethyltryptamine; N,N-D2-dimethyltryptamine; D2-DMT; DMT-d2
Routes of
administrationIntravenous injection, intramuscular injection[1]
Drug classSerotonin receptor modulator; Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Quick facts Clinical data, Other names ...
SPL028
Clinical data
Other namesSPL-028; α,α-Dideutero-N,N-dimethyltryptamine; N,N-D2-dimethyltryptamine; D2-DMT; DMT-d2
Routes of
administration		Intravenous injection, intramuscular injection[1]
Drug classSerotonin receptor modulator; Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Identifiers
PubChem CID
ChemSpider
Chemical and physical data
3D model (JSmol)
  • [2H]C([2H])(CC1=CNC2=CC=CC=C21)N(C)C
  • InChI=1S/C12H16N2/c1-14(2)8-7-10-9-13-12-6-4-3-5-11(10)12/h3-6,9,13H,7-8H2,1-2H3/i8D2
  • Key:DMULVCHRPCFFGV-MGVXTIMCSA-N
Close

Pharmacology

SPL028 shows similar pharmacodynamics as DMT in vitro.[2][6] Relatedly, SPL028 generalized with DMT in rodent drug discrimination tests.[6][7] On the other hand, SPL028 differs from DMT in terms of pharmacokinetics; it is more resistant to metabolism and shows a prolonged duration.[2][6][7] In a phase 1 clinical trial, SPL-028 by intramuscular injection produced robust psychedelic effects of short duration in humans.[8]

Research

SPL028 was originated by Small Pharma and is under development by Cybin.[4] Small Pharma was acquired by Cybin in 2023.[9] As of February 2024, SPL028 is in phase 1 clinical trials.[4]

See also

References

External links

Related Articles

Wikiwand AI